Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that in alopecia areata, treatment with the oral JAK-inhibitor tofacitinib decreased clonally expanded CD8⁺ T cells in the scalp, but many expanded clones did not completely disappear, potentially leading to relapse after stopping treatment.

In this study using the C3H/HeJ mouse model of alopecia areata, researchers found that hyperexpanded CD8⁺ T cell clones were sufficient to initiate disease, establishing a causal link between T cell clonality and pathogenicity.

In this study, researchers found that alopecia areata patients show a significant reduction in suppressive regulatory T-cells and an increase in inflammatory T-cell populations, suggesting an immunological imbalance contributing to the disease.

This open-label study found that oral tofacitinib led to significant hair regrowth in patients with moderate-to-severe alopecia areata, supported by changes in gene expression and T cell dynamics.

In this study, the researchers found that treatment with the JAK inhibitor tofacitinib in alopecia areata patients may reduce clonal CD8+ T cell expansions but does not eliminate them entirely, which could contribute to disease relapse.

In this study, blocking the CXCR3 receptor in mice prevented the development of alopecia areata by inhibiting the accumulation of specific T cells in the skin, suggesting a potential therapeutic approach for humans.

This study observed that patients with alopecia areata often have a T-cell receptor repertoire in skin lesions that suggests a specific antigen-driven immune response may be important in the disease's pathogenesis.

This study found that FOXN1 haploinsufficiency is a significant genetic factor causing T cell lymphopenia at birth, linked to reduced thymic function in both humans and mice.

This study found that in mice with alopecia areata, CD8+ T cells showed clonal expansion and specific regulatory networks, which might help identify new therapeutic targets for patients not responding to JAK inhibitors.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

This review discusses the role of the TCL1 transgenic mouse model in understanding chronic lymphocytic leukemia biology and highlights the importance of exploring new pathogenetic and therapeutic targets.

This study demonstrated that disrupting EGFR signaling in mice leads to immune sensitivity compromising the hair follicle's protective environment, but JAK1/2 inhibition can restore this immune privilege and stimulate hair growth, suggesting a potential therapy for scarring hair loss diseases like cicatricial alopecia.

In this study, researchers identified a specific T cell receptor associated with carbamazepine-induced severe cutaneous adverse reactions, demonstrating its potential for therapeutic development in patients with the HLA-B*15:02 genotype.

This review discusses current and potential treatments for alopecia areata, focusing on immunosuppressive and immunomodulatory approaches, but provides no new clinical results.

This study found that increased intracellular expression of thymosin β4 is necessary and sufficient to induce PAI-1 gene expression in endothelial cells, potentially mediated through Ku80 as a novel receptor.

This case report describes a patient with primary cutaneous natural killer/T-cell lymphoma, nasal type, where monoclonal Epstein–Barr virus genome expansion was associated with terminal aggressive behavior after an indolent clinical course.

This review discusses the impaired functionality of regulatory T cells in the pancreas during the development of Type 1 diabetes, highlighting their role in disease pathogenesis, potential of Treg-based therapies, and challenges in clinical applications.

In this study, subcutaneous recombinant human IL-12 showed a 43% partial response rate in early-stage mycosis fungoides patients refractory to previous treatments, with generally mild to moderate adverse events reported.

This study developed PiSCES biosignatures that distinguished alopecia areata patients from controls, revealing enhanced basal TCR signaling and a potential disease-specific signaling network signature.

This review examines integrins as pharmacological targets, discussing current integrin-based therapies and emphasizing the need to understand integrin mechanisms for successful drug development, without reporting new clinical results.

This study identified key genetic regions associated with alopecia areata, highlighting both acquired and innate immune involvement, with a novel link to the upregulation of ULBP ligands in autoimmune disease.

This review discusses the role of immune cells in the pathogenesis of alopecia areata and highlights emerging immunomodulatory strategies and novel therapeutic targets aimed at offering more effective and durable treatments for this autoimmune hair loss disorder.

In this study, researchers successfully established immortalized human frontal and occipital scalp dermal papilla cell lines from androgenetic alopecia patients, observing distinct gene expression, androgen receptor levels, and hair follicle growth effects between these regions, which may help advance hair loss research and therapeutic development.

This review assessed the role of scalp hair Survivin protein in individuals with premature graying, exploring its potential involvement in graying-related processes and highlighting its overexpression in autoimmune diseases that may influence the survival of specific immune cell clones.

This study developed immortalized human hair follicle-derived mesenchymal-like stromal cells (iHF-MSCs) as a consistent source of therapeutic secretome, reporting their superior immunomodulatory and regenerative performance, potentially advancing cell-free therapies for inflammation and tissue repair.

In this study, researchers found that disrupting EGFR signaling in mice led to increased inflammation and hair follicle damage but that inhibiting the JAK-STAT1 pathway could restore hair growth and skin function.

The researchers reported that hair follicle development and commensal microbe colonization promote the accumulation of regulatory T cells in neonatal skin, with the Ccl20-Ccr6 pathway playing a key role in this process.

This study found that basal cell carcinomas show strong expression of vitamin D receptors at both mRNA and protein levels, suggesting a potential role in tumor growth regulation.

This study found that selective androgen receptor modulators (SARMs) significantly inhibited tumor growth and metastasis-promoting factors in AR-positive triple-negative breast cancer models.

T cells and bacteria in the gut and skin help maintain health and protect against disease.